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Summary 
Genetic  studies  have  indicated  that  susceptibility  to  rheumatoid  arthritis  (R.A)  maps  to  the 
HLA-DP, locus  of the  major histocompatibility  complex.  Strong linkage  disequilibrium  be- 
tween  certain  HLA-DQ  genes  and  HLA-DP,. genes  associated  with  RA,  however,  suggests 
that  HLA-DQ  molecules  may also play a role in RA susceptibility.  To  examine  the  role  of 
HLA-DQ  molecules  in  arthritis,  we  generated  transgenic  mice  expressing  the  DQA 1"0301 
and DQB 1"0302 genes from an RA predisposing haplotype (DQ8/DR.4Dw4). The transgenes 
were introduced into mouse class II-deficient H-2Ab  ~ mice, and their susceptibility to experi- 
mental  collagen-induced  arthritis  was  evaluated.  The  HLA-DQ8+,H-2Ab  ~  mice  displayed 
good expression of the DQ8 molecule, while no surface expression of endogenous murine class 
II molecules could be detected. The DQ8 molecule also induced the selection of CD4 + T  cells 
expressing a normal repertoire  of V~ T  cell receptors.  Immunization of HLA-DQ8+,H-2Ab  ~ 
mice with  bovine type II collagen  (CII) induced  a  strong antibody response  that was  cross- 
reactive to homologous mouse  CII. Also,  in vitro proliferative  responses against bovine  CII, 
which were blocked in the presence  of an antibody specific for HLA-DQ and mouse  CD4, 
were detected.  Finally, a severe polyarthritis  developed in a majority of HLA-DQ8+,H-2Ab  ~ 
mice, which was indistinguishable  from the disease observed in arthritis susceptible B10.T(6R) 
(H-2Aq) controls. In contrast, HLA-DQ8-,H-2Ab  ~ fullsibs did not generate CII antibody and 
were completely resistant to arthritis.  Therefore, these results strongly suggest that HLA-DQ8 
molecules  contribute  to  genetic  susceptibility  to  arthritis  and  also  estabhsh  a  novel  animal 
model for the study of human arthritis. 
I 
t is widely accepted that a strong genetic component con- 
tributes  to the  susceptibility  or resistance  to certain hu- 
man autoimmune diseases (1). Attempts to identify the par- 
ticular genes involved in these disorders has been an area of 
major focus for many laboratories,  and  inroads  have been 
clearly  made.  Among  the  numerous  genes  studied,  one 
group that has garnered much attention  are the  genes en- 
coding the class I and class  II molecules of the HLA com- 
plex. Located on the short arm of chromosome 6, the pri- 
mary function of HLA class  I  and  II molecules  is to bind 
and present processed antigenic peptides to T  cells bearing 
receptors specific for the peptide-HLA complex. This pre- 
sentation  event  plays a pivotal role in shaping the  cellular 
immune  repertoire  and  dictating  the  nature  and  scope  of 
the immune response against a given antigen (2). 
A  role  for  HLA molecules  in  the  etiology  of autoim- 
mune  disease  derives from genetic studies  showing a clear 
association  between  the  presence  or  absence  of  certain 
HLA class  I  or II alleles,  as well as increased  or decreased 
susceptibility  to  a  particular  autoimmune  disorder.  A  dis- 
ease with a strong autoimmune foundation and HLA class 
II association is rheumatoid arthritis  (RA) 1.  In Caucasians, 
genetic  studies  initially  showed  a  high  prevalence  of the 
HLA-DR4Dw4 subtype among RA patients (3). Work us- 
ing different ethnic groups, however, has implicated other 
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of the HLA-DR  alleles associated with RA revealed that a 
large  proportion  of RA  patients  who  express  the  Dw1, 
Dw4,  Dw14,  Dw15,  or  Dw16  haplotype  bear  a  similar 
amino  acid  sequence  within  the  67-74  region  of  the 
HLA.DR[31  molecule  (4,  5).  This similarity prompted in- 
vestigators to put forth the "shared epitope" hypothesis for 
RA  susceptibility  (6).  The  hypothesis  states  that  a  critical 
element in conferring an increased risk for RA susceptibil- 
ity is possession of this  common epitope within  the HLA- 
DR[31  molecule. Whether strictly accurate or not, this hy- 
pothesis  has  had  a  tremendous  influence  in  accelerating 
progress toward the molecular definition of RA susceptibil- 
ity. However,  the functional  role for the  "shared epitope" 
in RA remains obscure. 
In general,  HLA genes are inherited  as a haplotype with 
a  low  recombination  frequency  between  loci  (7).  Also, 
linkage  disequilibrium  between  certain  DQB  genes  and 
particular  HLA-DR  genes  have  revealed,  for some  disor- 
ders,  a  much stronger association  at the  DQ  than  DR  lo- 
cus.  For  instance,  a  strong  association  of HLA-DQ8  and 
DQ6  with  susceptibility  and  protection,  respectively,  in 
type I  diabetes has been  demonstrated  (8,  9).  Also,  HLA- 
DQ  polymorphisms have been shown to play a role in in- 
fluencing  autoantibody  levels  in  primary  Sjogren's  syn- 
drome  (10)  and  myasthenia  gravis  (11).  Most  recently, 
Welsh  et al.  (12)  demonstrated an association between sus- 
ceptibility to the disease allopecia areata and HLA-DQ8.  In 
Caucasoids,  the DQB0301  (DQ7) allele has been shown to 
be  associated  with  a  majority  of HLA-DR4  alleles  (6), 
while  DQB0302  (DQ8)  is in linkage  disequilibrium  with 
DR4 among the Asian population  (13). More importantly, 
data  exists  showing  an  increased  frequency  of a  particular 
DQ  allele,  such as DQ7,  in RA patients  (14,  15). Also,  an 
interesting study analyzing Indian patients with RA showed 
that  100%  of the  patients  possessed the  DQ8  allele  versus 
33.3% in normal subjects (13). On balance, these data support 
a role for HLA-DQ  alleles in genetic predisposition to RA. 
To better understand  the  role of HLA molecules in au- 
toimmune  disease,  researchers  have  developed  transgenic 
animals  expressing  disease-associated  HLA  gene  products. 
Success using this approach was illustrated  by the develop- 
ment  of a  transgenic  rat  model  for  HLA-B27-associated 
spondyloarthropathy  (16).  Initial  studies  with  transgenic 
mice expressing human class II genes demonstrated that the 
HLA class  II molecules are functional  as shown by the in- 
trathymic deletion  of T  lymphocytes bearing certain V~ T 
cell receptors  (17,  18).  However, the consistent generation 
of human  class  II-restricted  immune  responses  in  these 
transgenic mice has been limited (19, 20). A possible reason 
for such poor responsiveness may be an inefficient interac- 
tion  between  the  mouse  CD4  coreceptor  and  the  human 
class II molecule  (21).  Recent  attempts  to circumvent  this 
problem  have  led  to  the  generation  of enhanced  human 
class  II-restricted immune  responses.  For instance,  Woods 
et  al.  (22)  constructed  a  human-mouse  chimaeric  HLA- 
DR4/H-2E  transgene  containing the mouse CD4-binding 
domain, while Fugger et al.  (23) recovered human class II- 
restricted  responses  in  HLA-DR4  transgenic  mice  coex- 
pressing the human  CD4 molecule.  Similarly, Yeung et al. 
(24) showed that expression of the human CD4 and HLA- 
DQ6  molecules  in  mice  bearing  disrupted  murine  CD4 
and CD8  genes reconstituted  the human  class  II-restricted 
limb of the immune system. In all cases, however, the abil- 
ity of these  mice  to mount  a  protective  or pathologic  re- 
sponse  against  a  known  pathogen  or  autoantigen  is  un- 
known.  Likewise,  deciphering  the  functional  role of HLA 
molecules  in  these  animals  may prove  problematic  given 
the  dominant  expression  of  endogenous  mouse  class  II 
molecules. 
An  alternative  approach  to  generate  human  class  II- 
restricted  responses  in  mice is to express the  HLA class  II 
transgene  in  animals  rendered  deficient  for mouse  class  II 
expression  through  gene  targeting.  Expression  of the  hu- 
man class II molecule in the absence of mouse class II gene 
products  should,  in  theory,  lead to  the  preferential  devel- 
opment of a population of human class II-restricted T  cells. 
With  this  hypothesis  in  mind,  therefore,  we  introduced  a 
transgene  encoding  the  c~  and  j3  chains  of  the  HLA- 
DQBI*0302,  DQAI*0301  molecule  (HLA-DQS)  into 
mouse  class  II-deficient  H-2Ab ~  mice.  The  HLA-DQ8 
molecule  was  chosen  because  of its  reported  association 
with  various  autoimmune  disorders,  such  as  RA  (13). 
Given the presence of local immune reactivity against type 
II  collagen  (CII)  within  inflamed  synovial  tissue  of some 
RA patients  (25),  we evaluated  the susceptibility  of HLA- 
DQ8+,H-2Ab ~ mice to the  experimental  disease collagen- 
induced arthritis (CIA), a model that bears many similarities 
to human RA  (26).  We report here that expression  of the 
HLA-DQ8  molecule  in  murine  class  lI-deficient  H-2Ab {} 
mice leads  to  the  selection  and  restoration  of a  peripheral 
CD4 +  T  cell  compartment.  Moreover,  immunization  of 
HLA-DQS+,H-2Ab ~ mice  with  CII  induced  a  vigorous 
anti-CII response that culminated in a severe inflammatory 
polyarthritis  in a majority of the animals.  These studies are 
the first report demonstrating the induction  of a pathogenic 
immune  response  in  human  class  II  transgenic  mice,  and 
they establish a unique  animal disease model to dissect the 
role of HLA class II molecules in human polyarthritis. 
Materials  and Methods 
Mice.  All mice used in this  study were bred and maintained 
in the pathogen-free Immunogenetics Mouse Colony of the Mayo 
Clinic. Generation ofB10.M-DQ8 transgenic mice was achieved 
as follows:  briefly, cosmids H11A and X10A,  which contain the 
DQA*0301  and DQB*0302  genes,  respectively, were provided 
by Dr. Jack Strominger  (Harvard University,  Cambridge, MA). 
Clone H11A is a 30-kb DNA fragment containing the DQA*0301 
gene and the DQB*0302 gene with a truncated promoter. Clone 
X10A  is  a  38-kb  DNA  fragment  containing  in  the  center, 
DQB*0302  gene (27).  The cosmid inserts  were released by SalI 
digestion, purified, and microinjected into  (CBA/J  ￿  B10.M)F 2 
embryos, as previously described  (28). Transgene-positive founders 
were identified by Southern blot analysis of tail DNA and subse- 
quently mated to B10.M mice. The HLA-DQ8 transgenes were 
introduced into H-2Ab  ~ mice as described in Fig.  1. Mouse class 
28  Experimental Arthritis in HLA-DQ8-transgenic Mice II-deficient H-2Ab  ~ mice were  kindly provided by Drs.  Diane 
Mathis  and  Christophe  Benoist  (INSEtLM,  Salsbourg,  France). 
Mice of both sexes were used in this study,  and they were 8-12 
wk old at the start of the experiment. 
Flow Cytometry.  Analysis of HLA-DQ8,  murine  class  I,  and 
class  II  expression  on  PBL was  achieved as  follows:  mice were 
bled via the tail artery and the white cell fraction was isolated by 
centrifugation  over  a  Ficoll-Hypaque  gradient.  After  extensive 
washing  in  PBS  containing  1%  BSA  and  0.1%  sodium  azide 
(PBS/BSA), the cells were incubated with one of the following 
mAbs:  IVD12,  anti-HLA-DQ  (29);  AF6-120,  anti-H-2A  b (30); 
7-16.7  anti-H-2A,  b  (kindly  provided  by  Dr.  David  McKean, 
Mayo Clinic, Rochester, MN); Y17,  anti-H-2E~  b (31);  and 28- 
14-8S,  anti-H-2D  b  (32).  After  a  30-rain  incubation,  the  cells 
were  washed  in  PBS/BSA and  then  incubated  with  an  FITC- 
conjugated goat Fab' 2 fragment specific for mouse IgG (Accurate 
Chemical & Science Corp., Westbury, NY). The cells were sub- 
sequently washed and fixed with 1% formalin before analysis.  To 
determine  the  level of CD4 §  and  V~  TCR-positive  cells,  the 
mice were killed and the peripheral lymph nodes were removed 
and  homogenized  to  dislodge  the  cells.  The  lymph  node  cells 
(LNC) were then extensively washed with PBS/BSA, and ,'o106 
cells were incubated with one of the following V~ TCR--specific 
mAbs: KT4, rat anti-V~4 (33);  MR9-4, mouse anti-V~5.1.2  (34); 
F23.2, mouse anti-V~8.2  (35);  14-2, rat anti-V~14 (36);  and KM 
114,  rat  anti-CD44  (37).  After  a  30-min  incubation,  the  cells 
were washed  then  incubated with  FITC-conjugated  Fab' 2 frag- 
ments specific for either mouse or rat IgG or rat  IgM (Accurate 
Chemical).  After 30 min,  the  cells were washed and then  incu- 
bated  with  a  1:1  mixture  of PE-  and  red 613-conjugated  mAb 
specific for mouse  CD4  and  CD8,  respectively (GIBCO  BILL, 
Gaithersburg,  MD).  Finally, the samples were washed and fixed 
with 1% formalin. Both single- and three-color fluorescent analy- 
sis were performed using a FACS  |  vantage flow cytometer (Bec- 
ton Dickinson & Co., Mountain View, CA). 
Induction of CIA.  Highly purified  native  bovine  and  mouse 
CII were isolated as described elsewhere (38).  Lyophilized bovine 
ClI  was  dissolved overnight at  4~  in  0.01  N  acetic  acid  then 
emulsified at a 1:1 ratio with CFA (Mycobacterium tuberculosis strain 
H37  ILa;  Difco  Laboratories,  Detroit,  MI).  The  animals  were 
subsequently immunized with 100 bel (100 mg bovine CII) of the 
emulsion at the tail base. 28 d later, the animals received a booster 
injection of 100 beg bovine CII emulsified in IFA. The mice were 
carefully monitored three  to  four times per week for the  onset 
and  progression  of CIA from  the beginning  of the  experiment 
until its termination at 12 wk after immunization. The severity of 
arthritis  was  evaluated  as  previously  described  (39)  based  on  a 
grading system for each paw as follows: 1 =  redness or swelling in 
paw  or toes;  2  =  severe swelling and/or joint  deformity;  3  = 
joint ankylosis.  The score per paw was summed to give a maxi- 
mal  possible  score  of 12  per  animal.  The  mean  CIA score  per 
group was determined using arthritic animals only. 
Anti-CII ELISA.  The  level of IgG antibody  reactive against 
bovine  and  mouse  CII was  determined  using a  highly sensitive 
ELISA technique (40). Briefly, day 35 sera from bovine CII-immu- 
nized mice was diluted in PBS containing 0.05% Tween 20 and 
0.2 M  NaC1 (PNT). Microtiter wells were coated with either bo- 
vine or mouse ClI dissolved in KPO  4 buffer, pH 7.6,  at 300 ml 
per well (20 beg/ml of ClI) overnight at 4~  After washing with 
PNT,  the wells were blocked with  1% BSA in PNT.  Duplicate 
serial  fourfold  dilutions  of sera  (1:100  to  1:6,400)  were  then 
added  to  the  wells and  incubated  at  4~  overnight.  The  wells 
were washed, incubated with a peroxidase-conjugated goat anti- 
mouse  IgG  (Organon  Teknika  Corp.,  West  Chester,  PA),  and 
the color was developed using O-phenylenediamine. The amount 
of total IgG anti-CII antibody was calculated by comparing OD 
values  with  a  high  titer  standard  sera  arbitrarily  determined  to 
contain 100 CII anitbody U/m] sera. 
In  Vitro LNC Proliferation.  Lyophilized  bovine  CII  was  dis- 
solved in 0.1  N  acetic acid overnight at a concentration of 2 rag/ 
ml and then emulsified 1:1 with CFA. Mice received an intrader- 
mal injection of 100 bel of cold emulsion at the tail base and 50 ILl 
in each hind footpad for a total of 200 beg bovine CII per mouse. 
10  d  later,  the animals were killed, and the draining LNC were 
isolated  and  suspended  to  a  concentration  of 107/ml  in  ILPMI 
1640 medium (GIBCO BILL) supplemented with 5% heat-inac- 
tivated horse serum, 25 mM Hepes buffer, 2 mM glutamine,  100 
U/ml penicillin, and 100  beg/ml streptomycin.  100  bel of the cell 
suspension,  containing 106 cells, were added per flat-bottom mi- 
crotiter wells (Coming Glassware, Coming, NY), and they were 
subsequently  challenged with  100  bel media  alone  or 50  beg/ml 
heat-denatured  (45~  for 5 min) bovine CII. For in vitro-block- 
ing studies, 20 bel per well of serial fivefold diluted (1:10 to 1:1,250) 
culture  supematant  containing  mAb  specific  for  HLA-DQ 
(IVD-12),  H-2A~,  b  (7-17.7),  H-2E~  b  (Y17),  mouse  CD4  (GK 
1.5),  mouse  CD8  (53.7.72),  control mouse IgG  (MB40.5,  anti- 
HLA-A,  -B,  and  -C),  or  rat  IgG  (M5/114,  anti-H-2A  b)  were 
added to the LNC in the presence of 50 beg/ml bovine CII. The 
cells were incubated 48 h at 37~  with 5% CO2 and 95% air and 
then pulsed with 1.8 IxCi of [3H]thymidine during the final 18 h 
of culture. The cells were harvested on glass fiber filters, and the 
extent  of [3H]thymidine  uptake  was  determined  using  a  liquid 
scintillation  counter  (model  3801;  Beckman  Instruments,  Palo 
Alto, CA). 
Histologic Evaluation.  Mice were killed at the end  of the ex- 
periment  and  histological sections  of the  hind  limbs  were  pre- 
pared by the Pathology Department  of the Mayo Clinic. Limbs 
were dissected, and the joints were decalcified for 3-4 d and then 
embedded  in  paraffin  blocks.  Sections that  were  "-~6 I.Lm thick 
were  cut  for  each  joint  at  differing  intervals,  mounted,  and 
stained with hematoxilyn and eosin before analysis. 
Statistical Analysis.  Statistical differences in the mean  arthritic 
severity and mean day of CIA onset between groups  was  deter- 
mined using the nonparametric Mann-Whitney U  test. 
Results 
Introduction  and  Expression  of the  HLA-DQ8  Molecule  in 
H-2Ab ~ Mice.  In an effort to understand  the role of HLA 
class II molecules in R.A, we introduced the RA-associated 
HLA-DQBI*0302  and  DQAI*0301  genes  (HLA-DQS) 
into mouse class II-deficient H-2Ab ~ mice. Fig.  1 illustrates 
the strategy to derive the HLA-DQ8+,H-2Ab  ~ line. Briefly, 
B10.M  (H-2  f)  mice  bearing  a  transgene  encoding  the 
DQ0301  (x and DQ0302  [3 chain genes of the HLA-DQ8 
molecule  were  mated  with  H-2Ab ~  mice  (41).  The  off- 
spring were screened for HLA-DQ8  expression by flow cyto- 
metric  analysis  of PBL  using  the  HLA-DQ  specific  mAb 
IVD12.  The  HLA-DQ8+,H-2Ab  f/~ progeny  were  inter- 
crossed,  and  segregation  of the  H-2Ab ~ and  H-2Ab f gene 
was  monitored  via  fluorescent  analysis  using  the  H-2A  C 
specific  mAb  3F-12  and  the  H-2Ab-specific  mAb  AF6- 
120.  The  offspring  that  typed  as  HLA-DQ8+,H-2Ab  ~176 
and  HLA-DQ8-,H-2Ab  ~176  were  selected  and  intercrossed 
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to  develop the  HLA-DQ8+,H-2Ab  ~ and HLA-DQ8-,H- 
2Ab  ~ lines. 
Fig.  2  A  shows  that  transgenic  HLA-DQ8+,H-2Ab  ~ 
mice expressed the HLA-DQ8 molecule on ~25% of the 
PBL  population, with a  maximum level of 40%  in some 
animals.  Given the  presence  of intracytoplasmic H-2A~  b 
and H-2E~  b chains in H-2Ab  ~ mice (41, 42), it was possible 
that hybrid A~b-DQ8~ or DQ8~-E~  b molecules were  also 
present in the HLA-DQ8+,H-2Ab  ~ line. To eliminate this 
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Figure 1.  Schematic  illustration  of the generation  of 
HLA-DQ8+,H-2Ab  ~ mice. Segregation of the HLA- 
DQ8  transgene was  monitored by  flow cytometric 
analysis of PBL  using the  HLA-DQ-specific mAb 
IVD12. Segregation of the mutant H-2A~  ~ gene was 
also evaluated by flow cytometry by monitoring the 
expression of the H-2A  f and H-2A  b molecules using 
the mAbs  3F-12 and AF6-120, respectively. 
possibility, PBL from HLA-DQ8+,H-2Ab  ~ mice were ana- 
lyzed  for  surface  expression  of the  H-2A~  b  and  H-2E~  b 
molecule.  Use  of the  H-2A~b-specific mAb  7-16.17  did 
not detect  expression of H-2A~  b in HLA-DQ8+,H-2Ab  ~ 
animals (Fig. 2  B). Surface expression of the H-2E~  b mole- 
cule using the H-2E~b-specific mAb Y17 was similarly un- 
detected.  The Y17  mAb, however,  reacted strongly with 
PBL from positive control B10.Ea  k transgenic mice, which 
express the H-2E~  b chain due to the presence of'the H-2E~  k 
H-2A(x b 
B 
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Figure 2.  Analysis  of  HLA-DQ8 
and murine MHC expression in 
transgenic HLA-DQw8+,H-2Ab  ~ 
mice. PBL  from HLA-DQ8+,  - 
H-2Ab  ~  mice, B10, HLA-DQ8-,- 
H-2Ab  ~  and  B10.Ea  k  animals 
were analyzed  by flow cytometry 
for surface expression  of the mol- 
ecules HLA-DQw8 (A), H-2A~  b 
(B), and H-2E~  b (C). The meth- 
odology and antibodies used for 
analysis are described in detail in 
Materials and Methods. Table 1.  Selection of Peripheral CD4  + T  Cells in HLA-DQ8 +, H-2Ab  ~ Mice* 
Percent CD4/V[3 LNC (x +  SD) 
Percent CD4  Percent CD4/CD44 
Strain  (x _+ SD)  (x -+ SD)  V~34  V[35.1.2  V~6  V~8.2  V[314 
HLA-DQ8 +, H-2Ab  ~  11.2  +  2.1  46.8  +  0.6  6.6 --- 1.6  6.5 +  0.5  7.2 +  1.6  8.0 +  0.1  7.7 +  1.6 
HLA-DQ8-, H-2Ab  ~  3.7  +  0.3  75.0 _  3.2  5.4 +- 2.6  9.3 -  1.7  7.1  -+ 2.9  14.4  +- 0.7  6.5 -  2.4 
B10.T(6R)  29.5  +  2.1  36.6  +  4.4  6.5 +  0.4  5.2 +  0.6  4.4 +  0.5  12.9  -  O.4  5.4 +- 0.9 
*  Lymph node cells were removed and analyzed by flow cytometry as described in Materials and Methods. The frequency of CD4+/V[3 TCR-posi- 
tive cells was calculated from the gated CD4 + population shown in the first column. The data are presented as the mean percent positive ceils +  SD 
of three animals per group. 
molecule  (Fig.  2  C).  As  expected,  HLA-DQ8+,H-2Ab ~ 
animals did not  express the  H-2A~  b chain,  and  expression 
of the MHC  class I molecule D b was present at a level sim- 
ilar  to  HLA-DQ8-,H-2Ab ~  and  B10  mice  (data  not 
shown). Thus, cell surface expression of the DQ8 molecule 
requires both the DQ 0301  o~ and DQ 0302  [3 chains. 
Selection  of Peripheral  CD4 +  T  Cells  in  HLA-DQw8+, - 
H-2Ab~  A  hallmark  feature  of  class  II-deficient 
H-2Ab  ~ mice  is a  paucity of peripheral CD4 +  T  cells. In 
general, H-2Ab  ~ animals contain  <5%  CD4 +  cells within 
the lymph nodes, and the majority of these cells express the 
CD44  (Pgp-1) antigen (41).  To determine if expression of 
the human  HLA-DQ8  molecule in H-2Ab  ~ mice induces 
the selection of CD4 + T  cells, LNC from HLA-DQ8+,H - 
2Ab  ~  and  negative  littermate  HLA-DQ8-,H-2Ab ~  mice 
were analyzed for the expression of CD4 and CD44 mole- 
cules.  As  a  comparative  control,  mouse  class  II~sutiqcient 
B10.T(6R)  mice, which bear the collagen arthritis suscepti- 
ble H-2Aq molecule (39), were also studied. Table 1 shows 
that  HLA-DQ8+,H-2Ab ~ mice  displayed a  threefold  in- 
crease in the level of CD4 +  LNC  versus  HLA-DQ8-,H- 
2Ab  ~ animals. Moreover, the frequency of double-positive 
CD4/CD44  (Pgp-1)  cells in the HLA-DQ8+,H-2Ab ~ line 
closely resembled mouse class II~uflicient B10.T(6R) mice. 
Similar to previous reports  (41),  "~  of the CD4 +  cells 
in  HLA-DQ8-,H-2Ab ~ mice  expressed the  CD44  mole- 
cule. Single positive HLA-DQ8~ or HLA-DQ8~ transgenic 
mice did not display an increase in CD4 + LNC, thereby il- 
lustrating the importance of appropriate HLA-DQ8  o~ and 
[3 pairing in the restoration of the  CD4 +  T  cell compart- 
ment.  Analysis of V~  TC1K  expression within  the  CD4 + 
population  showed  that  HLA-DQ8§  ~  mice  ex- 
pressed a variety of V~ TC1Ks.  In addition, distinct differ- 
ences in the level of some CD4+/V~  TC1K +  cells, such as 
Vf35  and  V~8.2,  was  detected  between  HLA-DQ8+,H - 
2Ab  ~  mice  and  transgene-negative  littermates  (Table  1). 
On balance, these data suggest that expression of the HLA- 
DQ8  molecule  in  H-2Ab  ~ mice  induces  the  selection of 
CD4+,V~TCR +  cells  ,  which  are  distinct from  the  small 
population of CD4 + lymphocytes normally present in class 
II-deficient H-2Ab  ~ mice. 
Production  of  CII  Antibody  in  HLA-DQ8+,H-2Ab ~  Mice. 
Typically, murine  CIA is induced in susceptible strains of 
mice bearing the H-2  q or H-2 r haplotype after immuniza- 
tion with ClI in CFA (39, 43).  Both humoral and cellular 
immune  responses against the CII molecule is essential for 
the development of severe chronic arthritis (44) and induc- 
tion  of CIA is  critically dependent  upon  the  presence  of 
CII-specific CD4 +, TC1K o~[3  + T  cells (45, 46). 
Given the putative association of the HLA-DQ8 allele in 
certain RA populations (13), it was possible that the HLA- 
DQ8+,H-2Ab ~  mice  possessed  the  potential  to  mount  a 
pathogenic immune  response  against CII,  a  molecule im- 
plicated in  [CA  (25,  47).  Therefore,  HLA-DQ8+,H-2Ab ~ 
animals, along with transgene-negative littermates, positive 
control  B10.T(6R)  and  negative  control  H-2Ab  ~  mice, 
were immunized with bovine CII in CFA and monitored 
for  the  generation  of a  CII-specific antibody.  Analysis of 
sera 35 d after immunization by ELISA revealed that HLA- 
DQ8+,H-2Ab ~ mice  mounted  a  strong  IgG  antibody re- 
sponse against bovine CII (Fig. 3). The level of bovine CII 
antibody was comparable to arthritis-susceptible B10.T(61K) 
controls,  and  no  CII  reactivity was  detected in  sera from 
HLA-DQ8-,H-2Ab ~ littermates or H-2Ab  ~ animals. More- 
over,  HLA-DQ8+,H-2Ab ~ sera  was  highly  cross-reactive 
against mouse  CII.  Like the reactivity against bovine  CII, 
the  level  of mouse  CII-reactive antibody  was  similar  to 
B10.T(61K)  sera, and the extent of cross-reactivity in both 
strains was >50%.  Although many mouse strains of various 
H-2  haplotypes  can  mount  antibody  responses  against  a 
heterologous CII species, strong reactivity against homolo- 
gous mouse CII is limited to strains that bear a CIA-suscep- 
tible H-2  haplotype  (48).  Thus,  the  generation  of mouse 
CII  reactive  antibody  in  HLA-DQ8+,H-2Ab  ~ mice  sug- 
gested that these animals may have the potential to develop 
collagen arthritis. 
In Vitro Proliferative Response Of HLA-DQ8+,H-2Ab ~ LNC 
against Bovine CII.  To  further  explore  the  immune  re- 
sponse of HLA-DQ8+,H-2Ab ~ mice against bovine CII, in 
vitro  LNC  prolferative responses  were  assessed.  Fig.  4  A 
shows that LNC from bovine CII-immunized HLA-DQ8 +,- 
H-2Ab  ~ mice  mounted  a  detectable proliferative response 
against bovine CI! in vitro (stimulation index >2.5), which 
is comparable to control B10.T(61K) mice. Also, addition of 
mAb  specific  for  the  human  HLA-DQ  or  mouse  CD4 
molecules inhibited the anti-bovine CII response by >90% 
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Figure 3.  Measurement  of CII antibody  in HLA-DQ8+,H-2Ab  ~  mice. 
Transgenic  HLA-DQ8+,H-2Ab  ~  mice, negative  littermate HLA-DQ8-,- 
H-2Ab  ~ animals, as well as control H-2Ab  ~ and B10.T(6PQ mice, were 
immunized on day 0 with 100 Ixg bovine CII in CFA, and they were 
boosted with 100 p,g bovine CII in IFA on day 28. Sera were collected 
on day 35, and the level of IgG antibody specific for bovine and mouse 
CII determined by ELISA. The data were obtained using 5-15 animals 
per group. 
(Fig. 4 B). No inhibition was observed in cultures contain- 
ing  mAb  specific  for  mouse  H-2A~  b,  H-2Er3 b,  or  CD8. 
These data indicate that CD4 § T  cells recognize and prolif- 
erate to bovine CII presented by the HLA-DQ8 molecule. 
Development of  Arthritis in HLA-DQ8+,H-2Ab ~ Mice.  To 
determine if the immune response against bovine CII was 
arthritogenic, bovine CII-immunized  HLA-DQ8+,H-2Ab  ~ 
mice, HLA-DQ8-,H-2Ab  ~ littermates, B10.T(6R) animals, 
and H-2Ab  ~ mice were monitored for the onset and devel- 
opment of CIA. As shown in Table 2, experiment 1, HLA- 
DQ8+,H-2Ab  ~ mice were highly susceptible to CIA. Among 
the 18 animals tested,  12 developed a noticeable arthritis in 
~5 wk after immunization which progressed to severe ar- 
thritis and persisted until the termination of the experiment. 
In general, both HLA-DQ8+,H-2Ab  ~ and B10.T(6R) ani- 
mals  developed  severe  inflammation, swelling,  and joint 
deformity in afflicted limbs (Fig. 5, B and C). Histologic ex- 
amination of arthritic hind limbs showed that the nature of 
the  inflammatory infiltrate was  similar in  both  strains;  a 
marked synovitis consisting of synovial cell hyperplasia, in- 
filtration of mononuclear cells,  and erosion of articular car- 
tilage and subchondral bone was observed (Fig. 5, E and H 
versus F  and /).  Transgene-negative HLA-DQ8-,H-2Ab  ~ 
littermates showed  no signs of clinical arthritis and histo- 
logic evidence of synovial inflammation was  not detected 
(Fig. 5, A, D, and G). Serum analysis revealed that both ar- 
thritic and nonarthritic HLA-DQ8+,H-2Ab  ~ and B10.T(6R) 
mice possessed the bovine CII~pecific IgG antibody that 
was cross-reactive against mouse CII. Also, no significant 
correlation in the level of CII antibody and the  develop- 
ment or severity of CIA was detected in either the HLA- 
DQS+,H-2Ab  ~ or B10.T(6R) strains (data not shown). 
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Figure 4.  In vitro LNC proliferative  response ofHLA-DQ8+,H-2Ab  ~ 
mice to bovine CII. (A) Adult HLA-DQ8+,H-2Ab  ~ mice were immu- 
nized in the tail base and hind footpads with a total of 200 b~g bovine CII 
in CFA. 10 d later, the mice were killed and the draining  LNC were cul- 
tured in vitro in the presence or absence of bovine CII. (/3) LNC from A 
were cultured in the presence of bovine CII and mAb specific for HLA- 
DQ, H-2A,~  b, H-2E~  b, mouse CD4, mouse CD8, or control IgG. The 
percent inhibition of the bovine CII response was calculated as follows: 
[1  -  (dicpm in the presence of nlAb/dicpm in the presence of control 
mAb)] X 100. 
To confirm our observations, a second HLA-DQ8+,H  - 
2Ab  ~ line that expresses the HLA-DQ8 molecule on "-'15% 
of PBL were immunized with bovine CI1 and monitored 
for  C1A.  Once again,  a  majority of HLA-DQ8+,H-2Ab  ~ 
mice  developed  CIA  (Table  2,  experiment  2).  Interest- 
ingly, the onset of clinical arthritis was significantly earlier 
in this HLA-DQ8+,H-2Ab  ~ line compared to B10.T(6R) 
mice. Likewise, the severity of CIA was significantly  greater 
in arthritic HLA-DQ8+,H-2Ab  ~ animals. Transgene-nega- 
tive HLA-DQ8-,H-2Ab  ~ littermates did not develop CIA, 
and antibody against bovine CII was not detected (data not 
shown). Therefore, these findings demonstrate that expres- 
sion of the  DR4-1inked HLA-DQ8 molecule in class  II- 
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Strain 
CIA parameters 
Percent HLA-DQ8  + 
cells in PBL  Clinical arthritis  Day of onset  Arthritis score* 
(x •  SD)  (positive/total)  Percent  (x -+ SE)  (x •  SE) 
Experiment 1  HLA-DQ8 +, H-2Ab  ~ 
(line 1)  30.8 _  4.9  12/18  67  39 •  3  6.7 •  0.8 
HLA-DQ8-, H-2Ab  ~  NA~  0/10  0  --  -- 
H-2Ab  ~  NA  0/10  0  --  -- 
B10.T(6R)  NA  17/23  74  41  +  4  5.8 •  0.8 
Experiment 2  HLA-DQ8  +, H-2Ab  ~ 
(line 2)  15.4  •  4.8  5/7  71  25 •  11t  9.0 •  0.6￿82 
HLA-DQ8-, H-2Ab  ~  NA  0/5  0  --  -- 
B10.T(6R)  NA  8/10  80  43 +  411  5.6 +  1.2￿82 
*Mice were immunized with 100 Ixg bovine CII in CFA on day 0 and boosted with 100 p,g bovine CII in IFA on day 28. All animals were moni- 
tored regularly for the onset and development of CIA until the ternaination of the experiment at 12 wk after immunization. 
*Mean arthritic score was calculated at the end of the study using arthritic animals only. 
~Not applicable. 
lip <0.01 
￿82 <0.05 
deficient H-2Ab  ~ mice  confers susceptibility  to  induction 
of CIA. 
Discussion 
The  data presented here  comprise the first report dem- 
onstrating the induction  of a  pathogenic  autoimmune  re- 
sponse in mice expressing a human MHC  class II molecule. 
By introducing an HLA-DQ8  transgene into murine  class 
II-deficient H-2Ab  ~ mice,  we  observed  that  this  human 
class II molecule induced selection ofa CD4 + T  cell popu- 
lation  and  conferred  susceptibility to  the  R_A-like disease 
CIA. Our findings establish a novel animal model to study 
autoimmune arthritis, as well as a means to functionally ad- 
dress a possible role for HLA-DQ molecules in genetic pre- 
disposition to KA. 
Previous studies suggested that the inability of the mouse 
CD4  coreceptor to interact efficiently with human  class II 
would  limit  the  experimental  usefulness  of HLA  class  II 
transgenic  mice.  The  results  in  this  study clearly demon- 
strate that mouse CD4  coreceptors can sufficiently interact 
with the HLA-DQ  molecule in the absence of endogenous 
mouse class II. Thus,  the interaction between mouse CD4 
and human  class II appears to be affinity oriented, and the 
absence of mouse  class II molecules within the thymus  of 
HLA-DQ8 +, H-2Ab  ~ mice successfully forces the selection 
of HLA-DQ8 restricted CD4 §  cells. Although the work of 
Vignali et al. (21) suggested a species-specific barrier in the 
binding of CD4 and class II molecules, it is possible that the 
structural  constraints that  hinder binding between  routine 
CD4  and human class II may be limited to HLA-DR,  and 
not HLA-DQ molecules. Altmann et al. (20), however, re- 
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cently  reported  that  HLA-DRl-transgenic  mice  mount 
equipotent  HLA-DRl-restricted T  cell  responses  to  the 
139-154  peptide  of human  myelin  basic  protein.  There- 
fore, together with our observations, it is clear that in cer- 
tain cases murine  CD4  can efficiently interact with HLA- 
class II molecules. Previous studies have identified regions 
within the [3  z domain of the MHC  class II [3 chain as puta- 
tive CD4  interaction sites (49,  50). Analysis of these inter- 
action sites within the [32 domain (amino acid residues 110, 
141,  and  142)  show  that  this  region  of the  HLA-DQ8[3 
chain is identical to the mouse H-2A[3 molecule, while the 
HLA-DR[3  chain  differs at  residues  110  and  141  (David, 
C. S.,  unpublished observations).  Clearly, studies examin- 
ing the processes mediating the selection of CD4 +  T  cells 
in  HLA-DQ8+,H-2Ab ~ mice  may identify additional re- 
gions on MHC  class II molecules involved in CD4 binding 
or shed light on the role of CD4 signalling in T  cell devel- 
opment. 
The level of peripheral CD4 + T  cells in HLA-DQS+,H - 
2Ab  ~ mice was lower than mouse  class II-sufficient, CIA- 
susceptible B10.T(6R)  mice. The frequency of CD4 §  cells 
in  HLA-DQ8+,H-2Ab ~ animals,  however,  was  threefold 
higher  than  HLA-DQ8-,H-2Ab ~  littermates.  Moreover, 
the CD4 + populations were distinct between the two lines 
based on expression of the CD44 molecule. When immu- 
nized with  bovine  CII,  strong antibody responses  against 
CII were measured in HLA-DQ8§  ~ mice. In addi- 
tion, in vitro proliferative responses against bovine CII that 
were  effectively inhibited by mAbs specific for HLA-DQ 
and mouse CD4 were detected. These results strongly sug- 
gest  that  the  response  against bovine  CII  is  mediated by 
CD4 +  T  cells restricted by the  HLA-DQ8  molecule.  Of Figure 5.  Clinical and histologic  presentation of collagen arthritis in HLA-DQ8+,H-2Ab  ~ mice. (A-C) The appearance  of a normal rear paw from a 
bovine ClI-immunized HLA-DQ8  ,H-2Ab  ~ mouse (A) contrasted with arthritic paws from an HLA-DQ8+,H-2Ab  ~ animal (B) and a positive  control 
BI0.T(6R.) mouse (C).  (D-/)  Cross-sections  of the hind foot from an arthritis-resistant  HLA-DQS-,H-2Ab  ~ mouse (D and G) compared with an ar- 
thritic  joint from HLA-DQS+,H-2Ab  ~ (E and H) and B10.T (6R) animals (F and/). D and G illustrate normal synovial lining, while E, F, H, and I show 
regions of mononuclear cell infiltration of the synovium with pannus formation and cartilage and subchondral bone erosions.  The magnifications  of each 
section are noted in the lower right-hand corner. The areas of tissue illustrated  in G, /4, and I are higher magnifications  of the boxed areas in D, E, and 
F, respectively. 
paramount importance was the finding that the anti-CII re- 
sponse  was  arthritogenic.  A  severe  inflammatory  poly- 
arthritis developed in a  majority of bovine CII-immunized 
HLA-DQ8+,H-2Ab  ~ mice. The histological changes in the 
arthritic lesions were  indistinguishable from  CIA-suscepti- 
ble B10.T(6R)  animals. The cellular infiltrate consisted pri- 
marily  of  mononuclear  cells  and  synoviocytes  with  few 
polymorphonuclear  cells,  and  they  closely  resembled  the 
lesions  found  in  RA.  This  observation  indirectly  suggests 
that  the  mechanisms  underlying  the  arthritic  process  in 
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for  prototypical  CIA.  Also,  the  susceptibility  of  HLA- 
DQ8+,H-2Ab  ~ mice  to  CIA is  reproducible  as  illustrated 
by the development of arthritis in a second group of HLA- 
DQ8+,H-2Ab  ~ animals,  which  expressed  a  lower level  of 
HLA-DQ8  +  cells  in  PBL.  Interestingly,  this  line  of mice 
developed  an  accelerated  and  more  severe  CIA  versus 
B10.T(6R)  controls.  Whether  this  difference  was  merely 
an exceptional observation or a distinct characteristic of this 
particular HLA-DQ8+,H-2Ab  ~ line requires further inves- 
tigation.  Nonetheless,  the data clearly show that expression 
of the  HLA-DQ8 molecule  confers susceptibility  to  CIA. 
Finally,  preliminary  studies  indicate  that  polymorphisms 
within  the  HLA-DQ  molecule  dictates  susceptibility  to 
CIA;  bovine  CII  immunized  HLA-DQ6+,H-2Ab  ~ mice 
mount  weak  responses  to  ClI  and  do  not  develop  ClA 
(Nabozny,  G.H.,  and  C.S.  David,  unpublished  observa- 
tions).  Given  the  lack  of association  between  HLA-DQ6 
and human RA, such data is of interest. 
To date,  identification of the antigens  and/or agents re- 
sponsible for the manifestations  in RA have not been un- 
equivocally demonstrated.  Candidate  antigens  include  tis- 
sue proteoglycans (51),  heat shock proteins,  (52)  as well as 
CII (53). The relative role for immunity against CII in RA 
pathogenesis remains controversial; however, extant in the 
literature  are  reports  clearly showing  the  presence  of ClI 
reactive  T  cells  (54),  B  cells  (25,  47),  and  antibody  (53) 
within inflammed synovium of RA patients.  Such anti-CII 
immunity is not observed in patients with other inflamma- 
tory joint  diseases  such  as  psoriatic  arthritis  (25).  In addi- 
tion,  CII-reactive antibody from RA patients can passively 
induce an inflammatory arthritis  in naive mice,  thus illus- 
trating its arthritogenic potential  (55).  Our finding that the 
HLA-DQ8 molecule  can  restrict  an  arthritogenic  CII re- 
sponse is intriguing and, at the very least, points to a possi- 
ble role for CII as an antigenic target in RA. Clearly, iden- 
tification of the precise regions on CII responsible for ClA 
in  the  HLA-DQ8+,H-2Ab  ~  strain  may  provide  insight 
concerning the contribution of ClI immunity in arthritis. 
The  successful  induction  of arthritis  in  mice  expressing 
an  HLA-DQ  molecule  raises  questions  regarding the  role 
of HLA-DQ alleles  in human arthritis.  Considered sine qua 
non for RA susceptibility,  a majority of recent research ef- 
forts  have  focused upon understanding  the  significance  of 
the HLA-DR-associated "shared epitope"  in RA. In con- 
trast,  less  extensive studies have dealt with HLA-DQ asso- 
ciations  in  this  disease.  Preliminary  studies  using  HLA- 
DR4  human  CD4  double-transgenic  mice  suggests  that 
these animals can be induced to mount HLA-DR4--restricted 
responses against CII, but fail to develop arthritis  (56). Re- 
cently, our laboratory has hypothesized a more prominent 
role  for HLA-DQ  alleles  in  RA  (57).  The  generation  of 
CIA in the HLA-DQ8+,H-2Ab  ~ transgenic mice provides 
a  useful  tool  to test  such  an hypothesis.  It is possible  that 
our  findings  may serve  as  a  model  for a  subset  of HLA- 
DQw8 +  RA  patients  with  strong  CII  immunity  or  as  a 
broader  model for RA in  general.  Regardless,  our results 
suggest that a more thorough examination regarding a po- 
tential  contribution  for  HLA-DQ  alleles  in  RA  is  war- 
ranted.  Quite possibly, an extended haplotype consisting of 
a  particular  HLA-DQ  and  HLA-DR  molecule  may ulti- 
mately be shown to be a necessary factor for the induction 
and progression of this disease. 
The potential research opportunities available via the use 
ofHLA-DQ8+,H-2Ab  ~ mice are exciting. The use of these 
animals  as a novel model to study autoimmune  arthritis  is 
obvious.  In addition  to  ClI,  other  potential  autoantigens 
and  arthritogens  such  as  bacterial  and  viral  superantigens, 
heat  shock proteins,  and  extracellular  matrix  proteins  can 
be  tested  in these  mice.  Also,  this  strain  provides a  useful 
vehicle  to  assess  the  therapeutic  efficacy of human  HLA 
class II-blocking agents in the modulation of a pathogenic 
in vivo immune response. Likewise, identification of TCR 
usage against  ClI in HLA-DQ8+,H-2Ab  ~ mice may open 
the  door  towards  identifying  homologous  human  TCRs 
important in RA. Finally, introduction of additional HLA- 
DQ or HLA-DR molecules in these mice will provide an 
opportunity  to  study  the  interactions  and  influences  of 
multiple  human  class  II  alleles  on  a  defined  immune  re- 
sponse.  Hopefully,  our  findings  have  laid  the  foundation 
for an exciting and fruitful new era in human autoimmune 
disease research. 
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